Latest news

• AbbVie takes anti-tau drug into phase II for Alzheimer's

  Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in

• Tau protein drug fails late-stage trial

  LMTX is thought to reduce the accumulation of the tau protein, which normally stabilizes neurons, into potentially toxic tangles. ... The LMTX data were presented at the Alzheimer's Association International Conference in Toronto.